J
Jade Biosciences, Inc. (JBIO)
NCM – Real Time Price. Currency in USD
25.23
+0.37 (1.49%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
25.23
+0.37 (1.49%)
At close: May 12, 2026, 4:00 PM EDT
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
| Name | Position |
|---|---|
| Dr. Andrew James King D.V.M., Ph.D. | President of Research & Development |
| Dr. Edward R. Conner M.D. | Chief Medical Officer |
| Mr. Bradford D. Dahms Ph.D. | CFO & Treasurer |
| Mr. Jonathan Quick | Senior Vice President of Finance |
| Mr. Tom Frohlich | President, CEO & Director |
| Ms. Amy Sullivan | Senior Vice President of Development Operations |
| Ms. Elizabeth Balta J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Lori Stewart | Senior Vice President of People |
| Ms. Sandy Lewis | Senior Vice President, Biometrics & Clinical Strategy |
| Ms. Valerie Fauvelle | Senior Vice President of Regulatory & Quality |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | S-8 | d61004ds8.htm |
| 2026-04-28 | DEFA14A | d116556ddefa14a.htm |
| 2026-04-28 | DEF 14A | d52810ddef14a.htm |
| 2026-04-22 | 8-K | d90643d8k.htm |
| 2026-04-17 | PRE 14A | d52810dpre14a.htm |
| 2026-04-02 | 8-K | d147217d8k.htm |
| 2026-03-06 | 10-K | ck0001798749-20251231.htm |
| 2026-01-05 | 8-K | d93206d8k.htm |
| 2025-12-23 | CORRESP | filename1.htm |
| 2025-12-22 | S-1 | d19711ds1.htm |